Alkem Labs launches epilepsy drug Perampil in India
Mumbai: Drugmaker, Alkem Laboratories, has recently announced the launch of Perampil (Perampanel) tablets 2 mg/4 mg/6 mg in India.
Alkem has launched Perampil, at 2 mg – Rs. 49/strip of 7 tablets, 4 mg – Rs. 180/strip of 15 tablets and 6 mg – Rs. 300/strip of 15 tablets.
"This product reaffirms Alkem's commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India," the company stated.
Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization.
The drug, Perampanel, has been approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial onset seizures in patients with epilepsy aged 4 years and older and also as an adjunctive therapy in treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.